OBJECTIVES: This study investigated oxidative stress in the liver, by determining hepatic expression and serum levels of g-glutamyltranspeptidase (GGT) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) in different stages of nonalcoholic fatty liver disease (NAFLD), and assessed whether GGT can differentiate between the various stages of NAFLD. METHODS: Expression of GGT and 8-OHdG was examined in biopsy specimens by immunohistochemistry, and serum GGT and 8-OHdG levels were measured by enzyme-linked immunosorbent assays in patients with simple fatty liver (n = 10), nonalcoholic steatohepatitis (NASH; n = 10) and, as a control, in alcoholic liver disease (ALD; n = 10). RESULTS: Hepatic tissue expression of GGT and 8-OHdG was seen in ALD, NASH and fatty liver patients. The percentage of hepatocytes positive for 8-OHdG expression and serum 8-OHdG levels was significantly higher in patients with NASH than simple fatty liver. Serum GGT levels were increased in all cases with ALD, NASH and fatty liver, and correlated significantly with serum levels of 8-OHdG in ALD and NASH, but not in simple fatty liver. CONCLUSIONS: Levels of GGT in fatty liver patients may compensate for mild oxidative stress by repressing 8-OHdG levels and preventing progression to NASH; however further oxidative stress leads to increased levels of 8-OHdG and the development of NASH.
Introduction
Nonalcoholic fatty liver disease (NAFLD), which was first described in 1980 1 , is a clinicohistopathological entity that resembles the histological changes seen in alcoholic liver disease (ALD) but occurs in subjects with little or no alcohol consumption. NAFLD is considered to be the hepatic manifestation of metabolic syndrome, 2 a collection of common abnormalities that includes insulin resistance, visceral obesity, hyperlipidaemia, g-Glutamyltranspeptidase in nonalcoholic fatty liver disease diabetes and hypertension. NAFLD is a spectrum of disorders beginning with simple fatty liver and progressing to nonalcoholic steatohepatitis (NASH) and cirrhosis.
The pathogenesis of NAFLD requires further elucidation. Insulin resistance and cytokine production are key mechanisms leading to fatty change in the liver and, perhaps, also to NASH. 3 Day and James 4 have suggested that a 'second hit', such as oxidative stress, is required to activate progression from NASH to liver cirrhosis, which is a known risk factor for hepatocellular carcinoma. Recent studies have suggested that oxidative stress may also contribute to clinical progression from simple fatty liver to NASH. 5 Markers used to assess oxidative stress include malondialdehyde and 4-hydroxy-2nonenal, which are products of lipid peroxidation, and 8-hydroxy-2′deoxyguanosine , which is a product of oxidative DNA damage mainly by hydroxyl radicals. 6 Both serum and urinary 8-OHdG levels have been reported to be sensitive biomarkers of oxidative stress 7 and reflect total oxidative DNA damage in the body. 8, 9 Intrahepatic 8-OHdG expression has been shown to be increased in NASH compared with fatty liver and normal liver, with 8-OHdG being particularly expressed in areas of active inflammation. 10 γ-Glutamyltranspeptidase (GGT), a plasma membrane-bound enzyme, plays an important role in the metabolism of glutathione, functioning as a catalyst of glutathione hydrolysis. 11 -13 The serum level of GGT is closely correlated with the state of the liver 14 and is effective in the diagnosis of ALD.
The primary role of cellular GGT is the metabolism of extracellular reduced glutathione, allowing precursor amino acids to be assimilated and reused for intracellular glutathione synthesis. 15 In oxidative stress, the level of oxidized glutathione increases and hepatic GGT is induced; this then dismantles the oxidized glutathione and converts it to reduced glutathione. GGT, therefore, has an important role in antioxidant defence systems at the cellular level and is a valuable marker of oxidative stress in NAFLD. 16, 17 The present study, investigated oxidative stress in the liver by determining hepatic expression and serum levels of GGT in different stages of NAFLD compared with hepatic expression and serum levels of 8-OHdG, and assessed whether GGT might be useful in differentiating between the various stages of NASH.
Patients and methods

PATIENTS
Patients with fatty liver and NASH diagnosed pathologically on the basis of percutaneous liver biopsy at the Department of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, between March 2005 and July 2011 were enrolled into the present study. In addition, patients with ALD, also diagnosed on the basis of percutaneous liver biopsy, were recruited for comparison. Patients positive for hepatitis B surface antigen or hepatitis C virus and those < 20 years of age were excluded from the study.
Standard demographic, clinical and full biochemical tests were carried out, including measurement of body mass index, and albumin, alanine transaminase, total cholesterol, glucose and glycosylated haemoglobin levels.
The study was conducted according to the principles of the Declarations of Helsinki dated 2005 during the study period 2005 -2007 and dated 2008 during the study period 2008 -2011. The protocol was approved by g-Glutamyltranspeptidase in nonalcoholic fatty liver disease the Ethics Committee of Fukuoka University Hospital. All patients gave written informed consent prior to their participation.
IMMUNOHISTOCHEMISTRY
Immunohistochemical examinations for GGT and 8-OHdG were performed as previously described for 8-OHdG 8, 18, 19 using nonfixed frozen liver specimens obtained from liver biopsies. Briefly, 5 µm-thick freshly cut sections were incubated in cold acetone for 30 min and then endogenous peroxidase activity was blocked by incubation for 30 min with 0.3% hydrogen peroxide in methanol at room temperature, followed by washing for 5 min in 0.01 M phosphate-buffered saline (PBS), pH 7.4. The specimens were then incubated in blocking buffer (10% skimmed milk in PBS) for 60 min, also at room temperature, before being incubated overnight at 4°C with blocking buffer plus primary antibody either to affinity-purified GGT (dilution 1 : 300; Wako Pure Chemical Industries, Tokyo, Japan) or to 8-OHdG (dilution 1 : 200; Nikken Seil, Shizuoka, Japan). After being washed three times with 0.01 M PBS, pH 7.4, the specimens were incubated with peroxidaseconjugated secondary antibody (Histofine ® Simple-Stain MAX-PO Multi; Nichirei Biosciences, Tokyo, Japan) for 1 h at room temperature. Peroxidase activity was detected using a liquid diaminobenzidine (DAB) substrate kit (Histofine ® simple-stain DAB solution, Nichirei Biosciences). The specimens were then counterstained with haematoxylin (Sigma-Aldrich, St Louis, MO, USA). After being washed with 0.01 M PBS, pH 7.4, the specimens were dehydrated in 95% ethanol for 1 min, 100% ethanol for 1 min and xylene for 5 min, and mounted under a coverslip using Permount™ (Thermo Fisher Scientific, Rockford, IL, USA).
The slides were viewed using a conventional light microscope. The pro -portion of cells with positively stained nuclei per field of view at × 400 magnification was calculated in five randomly selected fields in specimens stained for 8-OHdG expression and the mean was then calculated and expressed as the 8-OHdG-positive rate.
MEASUREMENT OF SERUM 8-OHDG AND GGT LEVELS
Blood samples were collected from all patients on admission to hospital using tubes without anticoagulant. The samples were allowed to clot and serum was separated by centrifugation (10 min at 3000 g) within 30 min of collection and stored at -30°C until analysed.
The serum samples were passed through ultrafiltration filters (Microcon ® Ultracel YM-10; Millipore, Billerica, MA, USA) to remove any large molecular weight substances (> 10 000 M r ). Serum levels of 8-OHdG were measured using the highly sensitive 8-OHdG Check enzyme-linked immunosorbent assay (ELISA) kit (Nikken Seil) according to the manufacturer's instructions. This competitive in vitro ELISA is specifically designed for the measurement of 8-OHdG in samples expected to have low levels of DNA damage. The concentration of 8-OHdG in each sample was determined by reference to a standard curve generated from samples provided in the ELISA kit. Levels of 8-OHdG were measured three times for each sample and the mean concentration calculated.
Serum levels of GGT were measured using the Qualigent ® GGT kit (Sekisui Medical, Tokyo, Japan) according to the manufacturer's instructions. Levels were measured three times for each sample and the mean concentration calculated.
STATISTICAL ANALYSES
The mean ± SD was calculated for each set of data. Comparisons between the groups were g-Glutamyltranspeptidase in nonalcoholic fatty liver disease performed using the Student's t-test. A Pvalue < 0.05 was considered to be statistically significant. All statistical analyses were performed using JMP ® software version 5.1 (SAS Institute Inc., Tokyo, Japan). Correlations between serum levels of GGT and serum levels of 8-OHdG among the patient groups were analysed by Pearson's correlation coefficient test.
Results
A total of 10 patients with fatty liver, 10 with NASH and 10 with ALD were recruited to the study and their demographic, clinical and biochemical characteristics are given in Table 1 . Patients with fatty liver were significantly younger than those with ALD or NASH (P < 0.01 for both). The body mass index of patients with NASH or fatty liver was significantly higher than that in patients with ALD (P < 0.05 for both). Albumin and alanine transaminase levels were significantly lower in patients with ALD than in those with NASH or fatty liver (P < NS, no statistically significant between-group differences (P > 0.05). g-Glutamyltranspeptidase in nonalcoholic fatty liver disease 0.05 for all). Total cholesterol was significantly lower in patients with ALD than in those with NASH (P = 0.016). The glucose (P = 0.043) level in NASH patients was significantly higher than in patients with fatty liver, and the glycosylated haemoglobin level was significantly higher in patients with NASH than in patients with fatty liver or ALD (P < 0.05 for both).
IMMUNOHISTOCHEMISTRY
Patients with ALD and NASH, demonstrated strong immunoreactivity to GGT in the bile canaliculi of hepatocytes in liver lobule zones 1 -3 and strong immunoreactivity to 8-OHdG in hepatocytes throughout the whole liver lobule (Fig. 1A, 1B, respectively) . In patients with fatty liver, however, only weak GGT immunoreactivity was demonstrated in the bile canaliculi of hepatocytes in liver lobule zones 1 -3, whereas 8-OHdG immunoreactivity was again demonstrated strongly in hepatocytes throughout the whole liver lobule (Fig. 1C ). There were no differences in the localization of GGT expression between ALD, NASH and fatty liver patients.
The percentage of cells positive for 8-OHdG was higher in NASH and ALD patients than in fatty liver patients, although this was statistically significant only between NASH and fatty liver patients (P < 0.001); there were no statistically significant differences between ALD and fatty liver or between ALD and NASH patients (Fig. 2) .
SERUM CONCENTRATIONS OF 8-OHDG AND GGT
Serum levels of 8-OHdG were increased in NASH and ALD patients compared with fatty liver patients; however, only the difference between NASH and fatty liver patients was statistically significant (P < 0.05) and there were no statistically significant differences between ALD and fatty liver or between ALD and NASH patients (Fig. 3) . Thus, the raised serum levels of 8-OHdG reflected the strong immunoreactivity for 8-OHdG seen in fatty liver, NASH and ALD patients.
Serum levels of GGT are given in Table 1 ; in all three groups GGT concentrations were above normal (normal GGT level < 47 U/l). Serum levels of GGT were higher in ALD and NASH patients than in patients with fatty liver, but these differences were not statistically significant.
There was a statistically significant correlation between serum levels of GGT and serum levels of 8-OHdG in patients with ALD (P = 0.042; Fig. 4A ) and NASH (P = 0.015; Fig.  4B ), but not in patients with fatty liver (Fig.  4C ).
Discussion
Westernization of the Japanese lifestyle has led to increased interest amongst the Japanese population in lifestyle-related diseases, but also increased incidence of obesity and of metabolic syndrome and its associated insulin resistance, hyperlipidaemia and hyper tension. Elucidation of the mechanisms underlying the progression of fatty liver to NASH within the spectrum of NAFLD, the hepatic manifestation of metabolic syndrome, is important; insulin resistance, 20 oxidative stress, 21 mitochondrial disorder, 22 adipocytokines, 23 endotoxins, 24 inflammatory cytokines 25 and increased hepatic iron 26, 27 may all be involved, with the inflammation and fibrosis caused by these various liver-damaging factors leading to the development of NASH.
Oxidative stress occurs when there is an imbalance between defence factors, such as superoxide dismutase and reduced glutathione, and reactive oxygen species such as superoxide. 28 Depletion of antioxidants such as glutathione, vitamin E, β-carotene or vitamin C and/or increased production of M Irie, T Sohda, K Iwata et al. g-Glutamyltranspeptidase in nonalcoholic fatty liver disease Oxidative stress is known to contribute to liver cirrhosis, 29 which is a clear risk factor for hepatocellular carcinoma. Oxidative stress markers, such as serum levels of 8-OHdG or 4hydroxy-2-nonenal, have been reported to be raised and antioxidants such as superoxide dismutase decreased in patients with NASH; 23, 30 however, no significant difference in serum 8-OHdG levels between NASH and fatty liver has been reported. 30 The enzyme, GGT, has an important role in reducing oxidized glutathione in oxidative stress. 31 Takigawa et al. 32 investigated serum GGT activity and determined correlations with serum antioxidants, various other plasma and serum oxidative stress related factors, urinary 8-OHdG and lifestyle factors in healthy Japanese people. On multiple regression analysis, they showed that GGT had significant associations with retinol, 8-OHdG and docosahexaenoic acid. 32 In oxidative stress, oxidized glutathione increases and hepatic GGT is induced; this then dismantles oxidized glutathione and converts it to reduced glutathione. Thus, hepatic GGT is thought to defend against liver and DNA damage caused by oxidative stress.
In the present study, the raised serum levels of 8-OHdG reflected the strong immunoreactivity of 8-OHdG seen on immunohistochemistry in fatty liver, NASH and ALD patients. Serum levels of GGT were correlated with serum levels of 8-OHdG in ALD and NASH patients, but not in fatty liver patients. Patients with fatty liver showed significantly lower serum 8-OHdG levels than NASH patients, but there was no difference in serum GGT levels. We suggest, therefore, that in mild oxidative stress conditions, as occurs in fatty liver, GGT is induced and is able to compensate for the oxidative stress, thereby limiting liver damage and preventing progression to NASH. If oxidative stress increases further so that GGT can no longer compensate, this is reflected in increased levels of 8-OHdG and progression from fatty liver to NASH.
In conclusion, in the present study serum levels of the oxidative stress marker GGT were increased in ALD, NASH and fatty liver patients. In contrast, although serum levels and hepatic expression of the oxidative stress marker 8-OHdG were also raised the level in fatty liver patients was lower than in ALD and NASH patients. It is speculated that this is due to induced GGT compensating for mild oxidative stress in fatty liver.
